| AVY |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$2.50 vs. cons $2.47 |
MEDIUM |
| AVY |
Report |
2Q26 revenue |
IN-LINE |
pred ~$2.31B vs. cons $2.30B |
MEDIUM |
| AVY |
Report |
2Q26 organic sales growth |
IN-LINE |
pred ~1.1% vs. cons 1.0% |
MEDIUM |
| AVY |
Guide |
3Q26 adjusted EPS guidance |
BETTER |
guide ~$2.56 vs. cons $2.51 (3Q26) |
MEDIUM |
| AVY |
Guide |
FY26 restructuring-savings outlook |
BETTER |
guide ~$58M vs. cons $55M (FY26) |
LOW |
| AVY |
Guide |
FY26 adjusted EPS framework |
BETTER |
guide implied ~$10.10 vs. cons $10.00 (FY26) |
MEDIUM |
| AVY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
MEDIUM |
| AVY |
Return |
5-day cumulative residual |
+5.5% (FOLLOW-THROUGH) |
A ~$2.50 EPS result versus $2.47 consensus plus a ~$2.56 3Q guide versus $2.51 would support upward FY26 revisions toward ~$10.10 from ~$10.00, with confirmation that the 2Q destocking trough is reversing and second-half productivity/Intelligent Labels ramps remain intact. |
MEDIUM |